DHR Maintained by RBC Capital -- Price Target Raised to $250
RBC Capital maintained an 'Outperform' rating for Danaher Corp (DHR) and raised its price target to $250.00 from $215.00. The stock is currently trading at $214.21, with a GF Value™ of $235.16, indicating it is 8.9% undervalued. Danaher has a GF Score™ of 82/100, reflecting strong performance. Insider activity shows significant selling, with $12.74 million in sales over the last three months.
How this was made
The 30-second read
Why it matters
The raised target may prompt a modest rally, but insider sales could temper enthusiasm.
Market read
Analyst upgrade for a large‑cap healthcare equipment company; potential short‑term buying interest.
What to watch
High trailing P/E of 38x suggests valuation premium; investors may weigh this against the target raise.
Background
Analyst rating updates are common drivers of short‑term price moves.
Ticker impact
RBC Capital raised its price target for Danaher Corp to $250, indicating a bullish outlook.
likely upward pressure as investors price in the higher target
The target increase of 16% signals confidence in growth; such upgrades historically prompt short-term buying.
Market effects
May lift sentiment for other life‑sciences and diagnostics peers.
US market focus; limited regional effect.
Modest, confined to healthcare equipment sector.
Counterpoint
Insider selling of $12.7 M could signal concerns despite the upgrade.
Key entities
- companyDanaher Corp
Global science and technology firm in life sciences.
- analystRBC Capital
Investment bank providing the rating upgrade.
%252FHealthcare%252520researchers%252520working%252520in%252520medical%252520lab%252520by%252520chokniti%252520via%252520Adobe%252520Stock.jpeg&w=2048&q=75)
